An optimized method for manufacturing a clinical scale dendritic cell-based vaccine for the treatment of glioblastoma.
Immune-based treatments represent a promising new class of therapy designed to boost the immune system to specifically eradicate malignant cells. Immunotherapy may generate specific anti-tumor immune responses, and dendritic cells (DC), professional antigen-presenting cells, are widely used in exper...
Guardado en:
Autores principales: | Sara Nava, Marta Dossena, Simona Pogliani, Serena Pellegatta, Carlo Antozzi, Fulvio Baggi, Cinzia Gellera, Bianca Pollo, Eugenio A Parati, Gaetano Finocchiaro, Simona Frigerio |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2012
|
Materias: | |
Acceso en línea: | https://doaj.org/article/9a178412ea32421cb631861727bb261b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Dendritic Cells and Cancer Immunotherapy: The Adjuvant Effect
por: Sara Nava, et al.
Publicado: (2021) -
Absence of AKT1 mutations in glioblastoma.
por: Fonnet E Bleeker, et al.
Publicado: (2009) -
INVOLVEMENT OF PERFORIN/GRANZYME B-DEPENDENT SIGNALING PATHWAY IN CYTOTOXIC ACTIVITY OF DENDRITIC CELLS TOWARDS HUMAN GLIOBLASTOMA CELLS
por: T. V. Tyrinova, et al.
Publicado: (2017) -
ROLE OF TNFα/TNF-R1-SIGNALING PATHWAY IN CYTOTOXIC ACTIVITY OF DENDRITIC CELLS AGAINST GLIOBLASTOMA CELL LINES
por: T. V. Tyrinova, et al.
Publicado: (2018) -
HIF-1α hampers dendritic cell function and Th1 generation during chronic visceral leishmaniasis
por: Akil Hammami, et al.
Publicado: (2018)